NCT02359526View on ClinicalTrials.gov

A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

December 31, 2016

Conditions
Diabetic Macular Edema
Interventions
DRUG

IlUVIEN

All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.

Trial Locations (4)

3000-548

Center for Clinical Trials - Association for Innovation and Biomedical Research on Light and Image, Coimbra

1050-085

Instituto de Retina de Lisboa, Lisbon

4200-319

Hospital de São João, Porto

2600-009

Hospital Vila Franca Xira, Vila Franca de Xira

All Listed Sponsors
lead

Association for Innovation and Biomedical Research on Light and Image

OTHER

NCT02359526 - A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients | Biotech Hunter | Biotech Hunter